- Description
- Specifications
Catalog #: PRO-536
Description:
The CD14 is produced from human CD14 transfected CHO-cells. Before transfection the complete human CD14-cDNA was amplified by PCR and cloned into expression vector p-POL-DHFR. The myeloid differentiation antigen CD14 acts as the major receptor for bacterial LPS. The dominant form of the recombinant wild type CD14 is the 50-kDa protein containing 335 amino acids.
Synonyms:
Monocyte differentiation antigen CD14, Myeloid cell-specific leucine-rich glycoprotein, CD14.
Source:
CHO-cells.
Purity:
Greater than 95.0% as determined by SDS-PAGE.
Solubility:
It is recommended to reconstitute the lyophilized CD14 in sterile 18MΩ–cm H2O not less than 100 µg/ml. Further dilutions should be made with phosphate buffered saline (PBS).
Formulation:
CD14 was lyophilized from a concentrated protein solution (1.0 mg/ml) containing phosphate-buffered saline, pH 7.2.
Stability:
Lyophilized CD14 although stable at room temperature for 3 weeks, should be stored desiccated below -18 °C. Upon reconstitution CD14 should be stored at 4 °C between 2-7 days and for future use below -18 °C.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.
Activity:
Up to 20 µg/ml CD14 inhibit binding of FITC-LPS (0.5 µg/ml) to 600,000 CD14+CHO transfectants (FACS).
Physical Appearance:
Sterile Filtered White lyophilized (freeze-dried) powder.
Usage:
Denovo Biotechnology's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
